ArticleJournal of managed care & specialty pharmacy2019

Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.

Holly Trautman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.